Boltz, backed by a16z and Bessemer, aims to take drug hypotheses to human-ready molecules on a computer
GabriCorso · x · 2026-11-18
Boltz founder GabriCorso thanked its investor lineup, including Bessemer, a16z, Amplify Partners, Zetta Ventures, Obvious Ventures, Greycroft, F Prime, and Benchling. The company's long-term goal: a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving their computer. The team says much remains to build, but daily progress keeps reinforcing that conviction.
More from Venture
- SEO consultant pitches 14 journalists a week, calls GEO "BS" — gaganghotra_ · 2026-11-18
- Boltz's long-term goal: hypothesis to human-ready molecule without leaving the computer — GabriCorso · 2026-11-18
- Boltz Lab now a daily tool for pharma scientists; partners include Pfizer, GSK, Takeda, BMS — GabriCorso · 2026-11-18
- Boltz raises $110M Series A for AI biomolecular design, partners with 6 top-20 pharma giants — GabriCorso · 2026-11-18
- Anthropic IPO: $70-78/share, up to ~$1.4T valuation, ~$90B raise with supplier private placement — RihardJarc · 2026-11-18
- Traders Buy Anthropic at $1.8T Valuation on Pre-IPO Perps, Calling It a No-Brainer — adamamcbride · 2026-11-18